Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G/UnitedHealth Program Models Driving OTC Sales By Identifying Consumers’ Health Needs

This article was originally published in The Pink Sheet Daily

Executive Summary

P&G and UnitedHealth launch a partnership to provide consumers diagnosed with high cholesterol with education and products that meet their needs.

You may also be interested in...



Digital Marketing: Health Care Brands' Window Into Consumers' Lives

OTC and wellness marketers should seek to integrate their brands with consumers’ lives, not just connect with their demographic or diagnosis, says Brent Walker, a digital marketing and ecommerce guru for health care consulting firm C2B Solutions.

Digital Marketing: Health Care Brands' Window Into Consumers' Lives

OTC and wellness marketers should seek to integrate their brands with consumers’ lives, not just connect with their demographic or diagnosis, says Brent Walker, a digital marketing and ecommerce guru for health care consulting firm C2B Solutions.

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS078455

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel